APRE

Aprea Therapeutics, Inc.

• TipRanks·3d ago

  Maxim Group Reaffirms Their Buy Rating on Aprea Therapeutics (APRE)

• NASDAQ·04/02 08:12

  Aprea Therapeutics Closes Oversubscribed $30 Mln Private Placement; Stock Down

• TipRanks·04/01 16:14

  Aprea Therapeutics Raises $30M to Advance Oncology Pipeline

• Reuters·04/01 12:30

  Aprea Therapeutics closes oversubscribed private placement raising $30 million gross proceeds

• Reuters·04/01 12:30

  APREA THERAPEUTICS ANNOUNCES CLOSING OF OVERSUBSCRIBED $30 MILLION PRIVATE PLACEMENT

• Dow Jones·03/31 14:13

  Aprea Therapeutics Price Target Maintained With a $7.00/Share by Wedbush

• Dow Jones·03/31 11:26

  Aprea Therapeutics Price Target Cut to $1.20/Share From $4.00 by HC Wainwright & Co.

• Dow Jones·03/31 11:26

  Aprea Therapeutics Is Maintained at Buy by HC Wainwright & Co.

• Benzinga·03/31 11:16

  HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Lowers Price Target to $1.2

• TipRanks·03/31 10:18

  Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright

• Reuters·03/31 10:10

  APREA THERAPEUTICS, INC. <APRE.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $1.2 FROM $4

• Reuters·03/31 07:39

  U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks

• NASDAQ·03/30 13:18

  Aprea Reports Confirmed Partial Response In APR-1051 Trial And Announced $30M Private Placement

• TipRanks·03/30 12:44

  Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial

• Benzinga·03/30 12:15

  Aprea Therapeutics Commences ~$30M Offering Of Warrants, Pre-Funded Warrants